Analyst firms · BofA Securities · TXG
BofA Securities TXG price target and rating history
10x Genomics Inc. (TXG) · Health Care
BofA Securities rates 10x Genomics Inc. (TXG) Neutral with a $54 price target, as of its latest action on Dec 12, 2023. It has published 3 rating actions on TXG since September 2021, including 1 upgrade and 2 downgrades. Across 4 firms with a TXG price target in the last 12 months, the median target is $69.
- Current rating
- Neutral
- Price target
- $54
- Median target, all firms
- $69
- Actions on TXG
- 3
BofA Securities price target on TXG
Every BofA Securities rating on TXG
- Dec 12, 2023
- Jul 15, 2022
- Sep 14, 2021
How other firms rate TXG
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Stephens | Equal-Weight | Oct 23, 2026 | |
| Argus Research | Buy | $110 | Sep 28, 2026 |
| UBS | Neutral | $68 | Sep 9, 2026 |
| RBC Capital Markets | Sector Perform | $70 | Sep 1, 2026 |
| William Blair | Outperform | Mar 31, 2026 | |
| Citigroup | Neutral | Dec 11, 2025 | |
| Morgan Stanley | Equal-Weight | $20 | Dec 2, 2025 |
Questions about BofA Securities and TXG
- What is BofA Securities's price target for TXG?
- BofA Securities's latest stated price target for 10x Genomics Inc. (TXG) is $54, from its action on Dec 12, 2023.
- What is BofA Securities's rating on TXG?
- BofA Securities rates TXG Neutral, a neutral rating, as of Dec 12, 2023.
- When did BofA Securities last change its view on TXG?
- On Dec 12, 2023, BofA Securities upgrades to Neutral from Underperform, price target $36 to $54.
- How does BofA Securities's TXG target compare with other analysts?
- Across 4 firms with a TXG price target in the last 12 months, the median target is $69.
More TXG rating histories
All BofA Securities ratingsTXG news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.